Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HA121-28 in advanced biliary tract malignancies
CTR20210379Phase 2Terminated
- Sponsor
- CSPC Pharmaceutical Group
- Start
- Mar 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ha121-28 in biliary cancer, intrahepatic cholangiocarcinoma (ICC), extrahepatic cholangiocarcinoma (eCCA), gallbladder cancer, sponsored by CSPC Pharmaceutical Group. Started Mar 2021; status: terminated.
02
Drugs
ha121-28
03
Conditions
biliary cancerintrahepatic cholangiocarcinoma (ICC)extrahepatic cholangiocarcinoma (eCCA)gallbladder cancer
Beyond the preview
Go deeper on CTR20210379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210379.